Oncopeptides AB (publ.) announced that the company has appointed Holger Lembrer as Chief Financial Officer, CFO, takes the office on January 18, 2023. Prior to joining the company, Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young.

Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.